Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Rilotumumab

EU orphan designation number: EU/3/14/1291   
Active ingredient: Rilotumumab
Indication: Treatment of gastric cancer
Sponsor: Amgen Europe B.V.
Minervum 7061, NL-4817 ZK Breda, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
31/07/2014 Orphan designation EMA/OD/012/14 (2014)5518 of 29/07/2014